ARTICLE | Distillery Therapeutics
Cancer
November 9, 2016 9:01 PM UTC
Mouse studies suggest inhibiting signaling between CCL3 and its receptors, CCR1 and CCR5, could help treat juvenile myelomonocytic leukemia (JMML) in Noonan syndrome patients harboring activating SHP-...